CervoMed’s Neflamapimod Fails Primary Endpoint in Phase 2b Trial
CervoMed said neflamapimod failed to meet the primary endpoint in a Phase 2b trial for Lewy body dementia.
Related stories
Nikkei futures pare declines, last down 2.3%
M impact | EQUITY | Oct 30, 2026, 03:29 AM UTC
Asian Tech Shares Slump as AI Spending Worries Spur Safety Bid
Tech shares slumped in Asia on Friday as concerns that rising AI spending may not deliver sufficient returns drove investors toward safer assets. The yen rose and bonds surged towa
M impact | EQUITY | Oct 30, 2026, 03:25 AM UTC
BGFEcomaterials to Cancel 14.5 Billion Won of Own Shares
BGFEcomaterials will cancel own shares worth 14.5 billion won.
M impact | EQUITY | Oct 30, 2026, 03:18 AM UTC
BGF Eco Materials to cancel 14.5 billion won in shares
M impact | EQUITY | Oct 30, 2026, 03:18 AM UTC
Acme Solar Signs PPA With NTPC for 400 MW FDRE Project
Acme Solar signed a power purchase agreement with NTPC for a 400 MW ISTS-connected FDRE project.
M impact | EQUITY | Oct 30, 2026, 03:17 AM UTC
ACME Solar Signs PPA With NTPC for 400 MW Project
ACME Solar signed a power purchase agreement with NTPC for a 400 MW ISTS-connected FDRE project.
M impact | EQUITY | Oct 30, 2026, 03:16 AM UTC